Ads
-
Related paper
- Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia
- CHRONIC MYELOID LEUKEMIA STUDY FOR RESPONSE PATTERN WITH TYROSINE KINASE INHIBITORS
- Effect of Previous Use of Hydroxyurea on the Formation of Response to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia
- Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: influence of coping strategies and psychological factors
- Tyrosine Kinase level and White Blood Cells Count in Untreated and Treated Chronic Myelogenous Leukemia Patients with BCR ABL gene
- Efficacy and Toxicity Assessment of Different Clinically Used Small Molecular Tyrosine Kinase Inhibitors by Computational Molecular Docking Method
- Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemia
- Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review)
- Treatment with Nilotinib 300 Mg Twice Daily in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Albanian Patients
- Changes in Loc285758 Expression in Response to Cytarabine- Based Treatment in Patients with Acute Myeloid Leukemia